Loading...
Market
Geographical expansion of Dupixent for COPD by end of 2024?
2
Resolution / Starting Odds
Approved in 1-2 additional regions • 33%
Approved in 3-4 additional regions • 33%
Approved in 5 or more additional regions • 34%
Official announcements by Sanofi and Regeneron
Story
Sanofi and Regeneron’s Dupixent Approved for COPD, 'Smoker's Lungs,' in EU
Jul 3, 2024, 05:15 AM
Sanofi and its partner Regeneron have received European Union approval on Wednesday for the expanded use of their Dupixent injection to treat patients with chronic obstructive pulmonary disease (COPD). This marks the first-ever targeted therapy for COPD, also referred to as 'smoker's lungs,' approved in the EU. Notably, the EU's approval process for Dupixent was faster than that of the United States, highlighting a rare instance of expedited clearance. The approval is expected to create a new growth avenue for the blockbuster drug.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than $100 million • 25%
$100 million - $200 million • 25%
$200 million - $300 million • 25%
More than $300 million • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%